Ignite Creation Date:
2025-12-25 @ 4:59 AM
Ignite Modification Date:
2025-12-26 @ 4:00 AM
Study NCT ID:
NCT06100718
Status:
RECRUITING
Last Update Posted:
2024-12-13
First Post:
2023-10-09
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Discovery of New Cancer in the 1-year Follow-up After Ischemic Stroke in Patients at Risk: The INVISIBLE-1 Study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000083242', 'term': 'Ischemic Stroke'}], 'ancestors': [{'id': 'D020521', 'term': 'Stroke'}, {'id': 'D002561', 'term': 'Cerebrovascular Disorders'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 370}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2022-01-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-12', 'completionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2024-12-09', 'studyFirstSubmitDate': '2023-10-09', 'studyFirstSubmitQcDate': '2023-10-19', 'lastUpdatePostDateStruct': {'date': '2024-12-13', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2023-10-25', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of participants with newly diagnosed cancer (occult cancer)', 'timeFrame': 'Within 1 year after ischemic stroke'}], 'secondaryOutcomes': [{'measure': 'Determination of occult cancer characteristics', 'timeFrame': 'Within 1 year after ischemic stroke', 'description': 'The description of the specific characteristics of occult cancers is defined by the location of the cancer, the histological type of cancer, the date of suspicion of cancer (e.g. via imaging), the type of investigation leading to the suspicion of cancer, the date of final diagnosis via histology, the presence of metastases at diagnosis, the type of treatment provided and the date of start of treatment.'}, {'measure': 'Long-term functional outcome using the modified Rankin Scale (mRS) in stroke patients with occult cancer', 'timeFrame': 'At 1 year after ischemic stroke', 'description': 'The mRS (ranging from 0-6) measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The higher the mRS score, the more disabled or dependent the patient (mRS 6 represents death).'}, {'measure': 'All-cause mortality rate and cause-specific mortality rate', 'timeFrame': 'At 1 year after ischemic stroke'}, {'measure': 'Rate of recurrent ischemic stroke, or systemic embolism in occult cancer-related stroke', 'timeFrame': 'Within 1 year after ischemic stroke'}, {'measure': 'Stroke severity assessed with the National Institutes of Health Stroke Scale (NIHSS) score in patients with occult cancer', 'timeFrame': 'Baseline', 'description': 'NIHSS score is used to quantify stroke severity. It ranges from 0 to a maximum of 42 points. The higher the score, the more extensive the stroke.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Cancer-related stroke', 'D-dimer', 'ESUS', 'Occult cancer', 'Ischemic stroke'], 'conditions': ['Cancer-related Stroke', 'Paraneoplastic Coagulopathy', 'Occult Cancer', 'Ischemic Stroke', 'Embolic Stroke of Undetermined Source', 'D-dimer']}, 'descriptionModule': {'briefSummary': "INVISIBLE-1 aims to prospectively follow patients up to one year after ischemic stroke to:\n\n1. Determine the cumulative incidence of occult cancer in patients with embolic stroke of undetermined source (ESUS) and elevated D-dimer\n2. Describe occult cancer characteristics and spontaneous course of occult cancer\n\nMethodology\n\nThe investigators will include 370 stroke patients with elevated D-dimer (≥ 820 μg/L) at the time of stroke, suspicion of ESUS after initial workup and without known cancer. The investigators will perform a follow-up telephone interview at one year to assess the occurrence of a new cancer and characterize the course of the disease.\n\nSignificance\n\nDetermining the real incidence of occult cancer in high-risk patients will help support the implementation of screening trials in the future. Faster detection and treatment of occult cancers would significantly impact patient' outcomes by offering faster cancer treatment and optimal secondary stroke prevention.", 'detailedDescription': 'INVISIBLE-1 is the first prospective study conducting a 1-year post-stroke follow-up telephone interview in preselected stroke patients at high-risk for occult cancer.\n\nINVISIBLE-1 aims to:\n\n1. Prospectively determine the cumulative incidence of occult cancer in patients with elevated D-dimer and ESUS within 1 year after the ischemic stroke\n2. Describe occult cancer characteristics and spontaneous course of occult cancer\n\nHypothesis\n\nElevated D-dimer and suspicion of ESUS at admission may predict an underlying unknown cancer at the time of index stroke. The investigators hypothesize that the cumulative incidence of newly diagnosed cancer within 1 year after stroke reaches 15% in patients presenting these characteristics. This percentage is higher than the 10% currently known according to available retrospective studies.\n\nProject design\n\nTo ensure the recruitment of the majority of potential occult cancer patients, the investigators set the D-dimer cut-off for inclusion of ≥ 820 μg/L at admission, based on our intern retrospective analyses of 1001 patients (OCCULT-5 score). In patients with ESUS, this cut-off was associated with a sensitivity of 91% and a specificity of 56% for the presence of an occult cancer diagnosed within 1 year after the index-stroke.\n\nAs suggested by the current evidence, the investigators decided to set the limit for diagnosis of new cancer at 1 year after the index stroke. Beyond this period, the causality is questionable in our opinion.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'This study aims to include 370 stroke-patients with elevated D-dimer (≥ 820 μg/L) at baseline and suspicion of ESUS after initial workup in emergency room.', 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Informed consent as documented by signature from patient or next of kin\n* Age ≥ 18 years old\n* Acute ischemic stroke with symptom onset within 48 h before admission\n* Acute ischemic stroke with:\n\n * persistent signs and symptoms of stroke lasting for ≥ 24 hours OR\n * acute brain infarction documented by computer tomography (CT) or MRI\n* D-dimer ≥ 820 μg/L measured after symptom-onset and within 24h after admission\n* Embolic stroke of unknown source (ESUS)\\* after initial work-up (acute cerebral imaging, 12-lead electrocardiogram, cardiac monitoring for at least 24h and echocardiography)\n\nExclusion Criteria:\n\n* Active cancer\\*\\* known at time of index-stroke\n* Intravenous Thrombolysis administrated prior to D-dimer measurement: Use of external laboratory value possible if available\n* New diagnosis of central nervous system cancer\n* Patient or next of kin (in case of lacking capacity) unlikely to be compliant or available for study follow-up interview\n\nESUS\\*: According to the definition from the NAVIGATE ESUS randomized trial: Non-lacunar ischemic stroke occurring in a patient in whom investigations did not show another specifically treatable underlying stroke etiology, primarily \\>50% stenosis in a proximal extracranial or intracranial artery, atrial fibrillation, other major-risk cardioembolic sources, or other determined etiology.\n\nActive Cancer\\*\\*: According to the definition from the International Society on Thrombosis and Haemostasis: Cancer diagnosed within the previous six months, recurrent, regionally advanced or metastatic cancer, cancer for which treatment had been administered within six months, or hematological malignancy that is not in complete remission for more than 5 years.\n\n► Patients with history of cancer not meeting these criteria anymore can be included in the study.'}, 'identificationModule': {'nctId': 'NCT06100718', 'acronym': 'INVISIBLE-1', 'briefTitle': 'Discovery of New Cancer in the 1-year Follow-up After Ischemic Stroke in Patients at Risk: The INVISIBLE-1 Study', 'organization': {'class': 'OTHER', 'fullName': 'Insel Gruppe AG, University Hospital Bern'}, 'officialTitle': 'Discovery of New Cancer in the 1-year Follow-up After Ischemic Stroke in Patients at Risk: The INVISIBLE-1 Study', 'orgStudyIdInfo': {'id': '2021-01797'}, 'secondaryIdInfos': [{'id': '2021-01797', 'type': 'OTHER', 'domain': 'KEK-Number'}]}, 'armsInterventionsModule': {'armGroups': [{'label': 'Study group', 'description': 'Acute ischemic stroke patients at high-risk for underlying occult cancer (elevated D-dimer and suspicion of ESUS at admission)'}]}, 'contactsLocationsModule': {'locations': [{'zip': '1011', 'city': 'Lausanne', 'state': 'Canton of Vaud', 'status': 'RECRUITING', 'country': 'Switzerland', 'contacts': [{'name': 'Michel Patrik', 'role': 'CONTACT', 'email': 'patrik.michel@chuv.ch', 'phone': '+41 79 556 8416'}, {'name': 'Davide Strambo', 'role': 'CONTACT', 'email': 'Davide.Strambo@chuv.ch', 'phone': '+4121 314 17 74'}], 'facility': 'Dept. of Neurology, Centre Hospital Universitaire Vaudois', 'geoPoint': {'lat': 46.516, 'lon': 6.63282}}, {'zip': '4031', 'city': 'Basel', 'status': 'RECRUITING', 'country': 'Switzerland', 'contacts': [{'name': 'Mira Katan, MD', 'role': 'CONTACT', 'email': 'Mira.Katan@usb.ch', 'phone': '+41 61 328 45 06'}, {'name': 'Johannes Frenger', 'role': 'CONTACT', 'email': 'Johannes.Frenger@usb.ch', 'phone': '+41 61 265 25 25'}], 'facility': 'Dept. of Neurology, Universitätsspital Basel', 'geoPoint': {'lat': 47.55839, 'lon': 7.57327}}, {'zip': '3010', 'city': 'Bern', 'status': 'RECRUITING', 'country': 'Switzerland', 'contacts': [{'name': 'Simon Jung, MD', 'role': 'CONTACT', 'email': 'Simon.jung@insel.ch', 'phone': '+41 31 63 2 43 27'}, {'name': 'Morin Beyeler, MD', 'role': 'CONTACT', 'email': 'Morin.beyeler@insel.ch', 'phone': '+41 31 66 4 12 26'}], 'facility': 'Dept, of Neurology, Inselspital, University of Bern', 'geoPoint': {'lat': 46.94809, 'lon': 7.44744}}], 'centralContacts': [{'name': 'Simon Jung, MD', 'role': 'CONTACT', 'email': 'simon.jung@insel.ch', 'phone': '+41 31 63 2 43 27'}, {'name': 'Morin Beyeler, MD', 'role': 'CONTACT', 'email': 'morin.beyeler@insel.ch', 'phone': '+41 31 66 4 12 26'}], 'overallOfficials': [{'name': 'Simon Jung, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Inselspital, University of Bern'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Insel Gruppe AG, University Hospital Bern', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}